Biogen

Patent cliffs & loss of exclusivity

A biotechnology company with a focus on treatments for neurological and neurodegenerative diseases. It was founded in 1978 and has headquarters in Cambridge, Massachusetts.

Company

Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/biogen-idec
Facebook URLhttps://www.facebook.com/biogenjapan
Full Address225 Binney Street Cambridge, MA 02142, USA
Instagram URLhttps://www.instagram.com/biogenjapan
Legal Entity IdentifierW8J5WZB5IY3K0NDQT671
LinkedIn URLhttp://linkedin.com/company/biogen-
Pitchbook URLhttps://pitchbook.com/profiles/company/10553-05

17 upcoming patent cliffs

DrugIngredientTypeCliff
  1. Avonexinterferon beta-1aBiologicMay 2015
  2. TysabrinatalizumabBiologicNov 2016
  3. Avonexinterferon beta-1aBiologicFeb 2024
  4. Plegridypeginterferon beta-1aBiologicAug 2026
  5. Plegridypeginterferon beta-1aBiologicAug 2026
  6. Plegridypeginterferon beta-1aBiologicAug 2026
  7. Plegridypeginterferon beta-1aBiologicAug 2026
  8. Plegridypeginterferon beta-1aBiologicAug 2026
  9. Plegridypeginterferon beta-1aBiologicAug 2026
  10. SPINRAZANUSINERSEN SODIUMSmall mol.Dec 2030
  11. SPINRAZANUSINERSEN SODIUMSmall mol.Dec 2030
  12. Aduhelmaducanumab-avwaBiologicJun 2033
  13. Aduhelmaducanumab-avwaBiologicJun 2033
  14. VUMERITYDIROXIMEL FUMARATESmall mol.Oct 2033
  15. TECFIDERADIMETHYL FUMARATESmall mol.Nov 2035
  16. TECFIDERADIMETHYL FUMARATESmall mol.Nov 2035
  17. SPINRAZANUSINERSEN SODIUMSmall mol.Mar 2036
  18. ZURZUVAEZURANOLONESmall mol.Aug 2037
  19. ZURZUVAEZURANOLONESmall mol.Aug 2037
  20. ZURZUVAEZURANOLONESmall mol.Aug 2037

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Biogen — patent cliffs & loss of exclusivity | CliffBio